<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274233</url>
  </required_header>
  <id_info>
    <org_study_id>SP-420-702</org_study_id>
    <nct_id>NCT02274233</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia</brief_title>
  <official_title>Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sideris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sideris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and amount of the study drug in the blood after
      increasing doses of SP-420. The study will be conducted in patients with β-thalassemia.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Changes in renal function parameters.
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of SP-420</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of SP-420</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Iron Overload</condition>
  <condition>Beta-Thalassemia</condition>
  <arm_group>
    <arm_group_label>1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg SP-420 once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg SP-420 once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg SP-420 once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg/kg SP-420 once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 mg/kg SP-420 once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 mg/kg SP-420 twice daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-420</intervention_name>
    <arm_group_label>1.5 mg/kg</arm_group_label>
    <arm_group_label>3 mg/kg</arm_group_label>
    <arm_group_label>6 mg/kg</arm_group_label>
    <arm_group_label>12 mg/kg</arm_group_label>
    <arm_group_label>24 mg/kg</arm_group_label>
    <arm_group_label>9 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has iron-overload secondary to β-thalassemia requiring chronic red blood cell
             transfusions and iron chelation therapy

          -  Subject weighs ≥35 kg

          -  Subject is willing to discontinue current iron chelation therapy at least 7 days prior
             to the first dose of SP-420 and for the duration of the study

          -  Serum ferritin ≥700 ng/mL and iron saturation ≥70% within 3 weeks before Baseline (Day
             1)

          -  Cardiac T2* score &gt;20 msec within 6 months before Baseline (Day 1)

          -  Willing to use contraception during the study

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Serum creatinine greater than the upper limit of normal

          -  Platelet count &lt;100 × 10^9/L

          -  Use of another investigational drug within the last 30 days

          -  Significant cardiac, renal, hepatic dysfunction or other clinically significant
             conditions that, in the opinion of the Investigator, would exclude the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sideris Pharmaceuticals, Inc. Sideris Pharmaceuticals, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Sideris Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sideris Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sideris Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sideris Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sideris Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sideris Investigative Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sideris Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sideris Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Lebanon</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chelation</keyword>
  <keyword>Iron Overload</keyword>
  <keyword>Thalassemia</keyword>
  <keyword>Transfusion</keyword>
  <keyword>Iron Chelation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

